PNC-27 in Thailand: Selective Anti-Cancer Peptide Therapy
PNC-27 is an investigational peptide designed to selectively disrupt cancer cell membranes by targeting MDM-2-overexpressing tumour cells while sparing healthy tissue. Its use at Peptides Thailand is strictly within physician-supervised clinical research protocols.
Doctor-prescribed PNC-27 in Thailand is available at Peptides Thailand under physician supervision, with clinical-grade, COA-verified sourcing. Its investigational oncology mechanism requires careful physician assessment, and it is only considered for highly specific clinical presentations with full informed consent.
How PNC-27 Works
PNC-27 operates through a sophisticated mechanism targeting the HDM-2 protein expressed on cancer cell membranes. The peptide forms transmembrane pores specifically in cancer cell membranes, leading to cell death while leaving normal cells unaffected. This selective action is based on the peptide's ability to recognize and bind to specific proteins that are overexpressed in cancer cells but not present in significant amounts on healthy cells.
Medical Review Status
Last reviewed: June 2026 | Next review: December 2026
Written by Dr. Michael Ackland · Medically reviewed by Dr. Ploy Pitayanon, MD, licensed by the Medical Council of Thailand
At a Glance
Peptide
PNC-27
Category
Injectable Peptide
Dosage
As prescribed by oncologist
Frequency
Per medical protocol
Administration
Subcutaneous injection
Potential Benefits
- · Selective targeting of cancer cells
- · Spares healthy tissue
- · Minimal side effects
Quality Matters
Why we use Clinical-Grade only
Certificate of Analysis
Every peptide we dispense comes with a third-party COA confirming purity and potency, never grey-market sourced.
Compounded in Thailand
Manufactured in Thai FDA-licensed compounding laboratories operating under GMP standards.
Physician-prescribed only
No dispensing without a prescription. Every protocol begins with a licensed physician consultation and clinical assessment.
Medical Disclaimer
The information on this page is intended for educational and informational purposes only and should not be considered medical advice, diagnosis, or treatment. Any therapies, consultations, or prescriptions are provided only following assessment by a licensed physician and where clinically appropriate. Individual results may vary and no specific outcomes are guaranteed. Certain compounds discussed may not be approved medicines registered with the Thai FDA for specific therapeutic indications. Nothing here should be interpreted as a recommendation to self diagnose, self treat, or replace consultation with a qualified healthcare professional.
Doctor's Note
Dr. Ploy Pitayanon, MD, Medical Lead
PNC-27 requires careful medical supervision and individualized dosing. Our clinics in Chiang Mai and Phuket provide comprehensive assessment, monitoring, and ongoing support to ensure safe and effective treatment outcomes.
Potential Benefits
Selective targeting of cancer cells
Spares healthy tissue
Minimal side effects
Multiple cancer cell targets
Rapid action on target cells
No known resistance development
Complementary to other treatments
Natural cell death induction
Targeted therapeutic approach
Research potential
Speak with a physician
Interested in PNC-27?
All protocols require a physician assessment before any prescription is issued. Book a free video consultation with an MCT-licensed doctor.
Treatment Protocol
Dosage
As prescribed by oncologist
Frequency
Per medical protocol
Duration
As determined by treatment plan
Administration
Subcutaneous injection
Safety guide
PNC-27 Side Effects & Safety
Frequency, contraindications, and who is a good candidate
Recent PNC-27 Research
Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells
Reviewed the mechanism by which PNC-27 and related peptides create selective membrane pores in cancer cells expressing HDM-2, inducing rapid tumour-selective apoptosis without harming normal cells (Biomedicines, 2024).
View on PubMedAnti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Expressed HDM-2
Showed PNC-27 co-localises with membrane-expressed HDM-2 on cancer cells, triggering selective transmembrane pore formation and cell death without toxicity to normal cells (Ann Clin Lab Sci, 2024).
View on PubMedPNC-27, a Chimeric p53-Penetratin Peptide, Binds to HDM-2 and Kills Cancer Cells
Demonstrated PNC-27 binds HDM-2 expressed on cancer cell membranes and forms pores selectively in tumour cells, supporting its development as a non-toxic anticancer peptide (Biomedicines, 2022).
View on PubMedRelated Peptides
Prefer to message first?
Chat with our team on WhatsApp. We typically reply within minutes.
Chat about PNC-27